Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700899 | 1.00 | CNR2 (0.40) | CNR2PLA2G4BPLK1CYP3A4CYP2C9 | |
| SCHEMBL4562628 | 0.88 | PLK1 (0.36) | CNR2PLA2G4BPLK1CYP3A4CYP2C9 | |
| SCHEMBL1552126 | 0.87 | CNR2 (0.34) | CNR2PLA2G4BPLK1CYP3A4CYP2C9 | |
| SCHEMBL1552093 | 0.87 | CNR2 (0.34) | CNR2PLA2G4BPLK1CYP3A4CYP2C9 | |
| SCHEMBL537022 | 0.87 | CNR2 (0.34) | CNR2PLA2G4BPLK1CYP3A4CYP2C9 | |
| SCHEMBL45412 | 0.86 | NR5A1 (0.49) | CNR2PLK1PTPN11NR5A1TP53 | |
| SCHEMBL38944 | 0.86 | NR5A1 (0.49) | CNR2PLK1PTPN11NR5A1TP53 | |
| SCHEMBL78927 | 0.86 | NR5A1 (0.49) | CNR2PLK1PTPN11NR5A1TP53 | |
| SCHEMBL22216823 | 0.86 | NR5A1 (0.49) | CNR2PLK1PTPN11NR5A1TP53 | |
| SCHEMBL1309485 | 0.86 | NR5A1 (0.49) | CNR2PLK1PTPN11NR5A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947540-B1 | METHOD FOR STABILIZING THERMOPLASTIC RECYCLATES, STABILIZED PLASTIC COMPOSITIONS, AND MOLDING COMPOUNDS AND MOLDED PARTS PRODUCED THEREFROM | FRAUNHOFER GES FORSCHUNG (DE) | 2023-08-16 | — | — | EP | disclosed |
| US-20110015315-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | FREY MARKUS | 2011-01-20 | — | — | US | disclosed |
| US-6593403-B1 | Additive mixture for improving the mechanical properties of polymers | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015315-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | PNMT, PAH, PAOX | CNR2 1066/4885PLA2G4B 3940/4885PLK1 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.